Evonik's Next Move Hinges on a Single Word: Access

Evonik's stock is doing what stocks in the middle of a takeover standoff do best — hovering just shy of its recent peak while the market waits for someone to blink. The specialty chemicals maker closed Thursday at EUR 21.24, a whisker away from the 52-week high of EUR 21.84 it notched a day earlier, a gap of roughly 2.7%. That proximity is no accident. It is the price of a bid that has been made, rejected, and left dangling.

At the center of the stalemate sits a deceptively simple demand. BASF, according to media reports, is willing to sweeten its offer for its Ludwigshafen neighbor — but only after it gets a look inside the books. Evonik's management, which turned down an initial approach in late September at EUR 22.15 per share, has said plainly that no talks with its rival are underway. Until that logjam breaks, the spread between what BASF has put on the table and what Essen thinks it is worth stays frozen.

For shareholders, the due diligence question is the whole ballgame. Refuse it outright and the takeover scenario loses its engine. Open the door to confidential soundings and a formal negotiation phase — and, in all likelihood, a richer bid — comes into view.

A Rejected Bid, a Conditional Upgrade

The mechanics of the standoff are straightforward. BASF's first move, reported at EUR 22.15 per share, was dismissed as inadequate. Word from the German chemicals giant's camp suggests it would go higher, but not without first reviewing the balance sheet and the risks. A bid substantial enough to overcome Evonik's independence concerns would need to clear that EUR 22.15 mark by a comfortable margin.

Analysts have already adjusted their models to the new reality. Sebastian Bray of private bank Berenberg upgraded the stock from "Sell" to "Hold" on October 5, lifting his price target from EUR 15.50 to EUR 20.00. His reasoning: BASF's interest should underpin the shares even if operational headwinds persist. A day later, Parmantier & Cie reiterated a "Hold" rating with a EUR 20.50 target in a sector study. A formal offer carrying a proper premium, the thinking goes, could push the stock well past Wednesday's EUR 21.84 peak.

Japan, Pharma, and the Case for Paying Up

While the boardroom drama plays out, Evonik has kept its operational agenda moving. On Tuesday the company launched a partnership in Japan with Toyotsu Chemiplas and Sanyo Chemical to build a chemical recycling model for polyurethane foam, using Evonik's hydrolysis-based process to recover polyols and amines. The group is also advancing a biodegradable polymer platform for EUDRAGIT excipients in its pharmaceutical division. In a friendly market, such initiatives give a potential suitor additional reason to commit capital.

The Resistance Beyond the Boardroom

The obstacles to a deal are not confined to the negotiating table. Political and labor opposition has hardened. Mona Neubaur, North Rhine-Westphalia's economics minister, has spoken out against a BASF takeover, though the state parliament rejected an SPD motion to examine a state stake. Union representatives have been blunter still: Michael Vassiliadis and Alexander Bercht of IG BCE questioned a full sale of the RAG Foundation's holding in a letter to the works councils of both companies.

That skepticism carries weight because the RAG Foundation is Evonik's largest shareholder and, about a week ago, its board convened an extraordinary meeting on the BASF interest without taking a public position. If the foundation and other core holders signal they have no appetite to sell, BASF loses its strategic footing for pushing further.

What a Collapse Would Cost

Should BASF run out of patience and walk away, the takeover premium that has built up across the market would evaporate quickly. The shares have climbed 59% since the start of the year, and a meaningful chunk of that run is owed to the speculation of recent weeks. Strip out the bid support and the fundamental drags come back into sharp relief — chief among them the methionine price pressure that analysts have flagged. The stock would then have to be judged on its own numbers, with a swift move back toward pre-speculation valuation levels a real possibility.

As long as the market expects a deal or at least the start of book reviews, the shares look cushioned at the lower end of their range. A definitive breakdown in negotiating willingness, however, points to a meaningful valuation discount for anyone still holding.

November 3 as the Reckoning

The next hard data point comes from the company itself. Evonik will report third-quarter 2026 results on November 3, 2026 — a date that will show whether the standalone earnings power is strong enough to justify the current valuation without the help of a takeover premium. Until then, the stock's fate rests on a single word from Essen: access.